Related Experiment Video

Updated: May 23, 2025

Isolation and Differentiation of Stromal Vascular Cells to Beige/Brite Cells
07:22

Isolation and Differentiation of Stromal Vascular Cells to Beige/Brite Cells

Published on: March 28, 2013

38.6K

The therapeutic potential of Rosiglitazone in modulating scar formation through PPAR-γ pathway

Qing-Qing Fang1, Yang-Jun Gu2, Yong Wang1

  • 1Department of Plastic Surgery, Sir Run Run Shaw Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang Province, PR China.

European Journal of Pharmacology
|March 7, 2025
PubMed

Insights

Rosiglitazone, a PPAR-γ agonist, effectively reduces scar formation by modulating glucose and lipid metabolism. This study highlights its potential as a novel therapeutic for scar treatment.

Area of Science:

  • Biochemistry
  • Dermatology
  • Pharmacology

Background:

  • Scar prevention and treatment remain a significant medical challenge.
  • There is a need for safe, effective, and affordable scar therapies.
  • Metabolic pathways, particularly glucose and lipid metabolism, are implicated in scar development.

Purpose of the Study:

  • To investigate the role of peroxisome proliferator-activated receptor-γ (PPAR-γ) in scar formation.
  • To evaluate the efficacy of rosiglitazone, a PPAR-γ agonist, in mitigating scar formation.
  • To elucidate the underlying mechanisms of rosiglitazone's action on scar tissue.

Main Methods:

  • Non-targeted metabolomics and RNA sequencing were employed to analyze scar tissue.
  • Scar models were established in rats, and rosiglitazone was administered.
  • In vitro studies used transforming growth factor β1 (TGF-β1) stimulated fibroblasts (NIH 3T3 and 3T3 L1).

Main Results:

  • Activation of PPAR-γ by rosiglitazone significantly impeded fibrosis and reduced scar formation in vivo and in vitro.
  • Rosiglitazone downregulated inflammatory factors, triglyceride, lactic acid, glycogen, and lactate dehydrogenase levels.
  • Rosiglitazone increased adenosine triphosphate (ATP) production, free fatty acid levels, and the activity of key metabolic enzymes.

Conclusions:

  • Rosiglitazone demonstrates significant potential as a therapeutic agent for scar reduction.
  • Modulation of glucose and lipid metabolism via PPAR-γ activation is a key mechanism in scar mitigation.
  • These findings provide a mechanistic basis for using rosiglitazone to alleviate fibrosis and reduce scar formation.
Keywords:
Glycolipid metabolismInflammationInflammatory cytokinesPPAR-γRosiglitazoneScar formation

More Related Videos

Studying TGF-β Signaling and TGF-β-induced Epithelial-to-mesenchymal Transition in Breast Cancer and Normal Cells06:54

Studying TGF-β Signaling and TGF-β-induced Epithelial-to-mesenchymal Transition in Breast Cancer and Normal Cells

Published on: October 27, 2020

12.7K
Mechanism of Kemeng Fang's Inhibition of Podocyte Apoptosis in Rats with Membranous Nephropathy through the PI3K/AKT Signaling Pathway07:15

Mechanism of Kemeng Fang's Inhibition of Podocyte Apoptosis in Rats with Membranous Nephropathy through the PI3K/AKT Signaling Pathway

Published on: August 23, 2024

304

Related Concept Videos

Oral Hypoglycemic Agents: Biguanides and Glitazones01:26

Oral Hypoglycemic Agents: Biguanides and Glitazones

Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
149
TGF - β Signaling Pathway01:16

TGF - β Signaling Pathway

The TGF-β signaling pathway regulates cell growth, differentiation, adhesion, motility, and development. TGF-β ligands that induce TGF-β signaling are synthesized in their latent form. Several proteases or cell surface receptors such as integrins act upon the latent form, releasing the active ligand. There are three types of mammalian TGF-βs: (TGF-β1, TGF-β2, and TGF-β3) that bind as homodimers or heterodimers to TGF-β receptors. The TGF-β receptors...
7.2K
Clinical Applications of Epidermal Stem Cells01:19

Clinical Applications of Epidermal Stem Cells

Epidermal stem cells (EpiSCs) are mainly located at the basal layer of the epidermis. These cells repair minor injuries of the skin and replace dead skin cells. However, EpiSCs’ cannot heal severe wounds such as major burns or those from diabetes or hereditary disorders. In such cases, culturing the epidermal stem cells from the patient is possible and has yielded successful treatment options, such as laboratory-grown skin grafts. These grafts are synthesized using a patient’s own...
2.7K
Glucagon-like Receptor Agonists01:24

Glucagon-like Receptor Agonists

Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
289
PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a...
3.4K
Dipeptidyl Peptidase 4 Inhibitors01:23

Dipeptidyl Peptidase 4 Inhibitors

Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
155